XBiotech Inc. (NASDAQ:XBIT - Get Free Report) Director John Simard bought 368,524 shares of the stock in a transaction dated Monday, October 26th. The stock was bought at an average cost of $1.93 per share, for a total transaction of $711,251.32. Following the acquisition, the director directly owned 4,191,690 shares of the company's stock, valued at approximately $8,089,961.70. This represents a 9.64% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
XBiotech Stock Performance
Shares of NASDAQ:XBIT opened at $1.99 on Thursday. The firm has a fifty day moving average price of $2.17 and a 200 day moving average price of $2.33. XBiotech Inc. has a fifty-two week low of $1.80 and a fifty-two week high of $3.44. The firm has a market cap of $60.68 million, a price-to-earnings ratio of -1.34 and a beta of 0.79.
XBiotech (NASDAQ:XBIT - Get Free Report) last posted its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.25).
Wall Street Analyst Weigh In
Separately, Weiss Ratings raised shares of XBiotech from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, October 16th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat, the stock presently has a consensus rating of "Sell".
Check Out Our Latest Research Report on XBiotech
Hedge Funds Weigh In On XBiotech
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in XBiotech during the 2nd quarter valued at approximately $739,000. Empowered Funds LLC bought a new stake in XBiotech in the 2nd quarter worth approximately $137,000. Bank of New York Mellon Corp bought a new stake in XBiotech in the 2nd quarter worth approximately $91,000. GSA Capital Partners LLP bought a new stake in XBiotech in the 2nd quarter worth approximately $71,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of XBiotech during the 2nd quarter worth approximately $64,000. 55.70% of the stock is owned by institutional investors.
About XBiotech
(
Get Free Report)
XBiotech, Inc is a biotechnology company focused on discovering, developing and commercializing therapies based on True Human antibodies. Its research platform is designed to produce fully human antibodies that target specific biological pathways involved in inflammation and other serious diseases.
The company's leading investigational product is bermekimab, an antibody designed to neutralize interleukin-1 alpha, a protein associated with inflammation and disease progression. Bermekimab has been evaluated in clinical studies involving conditions including cancer, inflammatory skin diseases and other disorders.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
